Literature DB >> 29995722

Temporal Differences in Utilization of Intracytoplasmic Sperm Injection Among U.S. Regions.

Pavel Zagadailov1, Albert Hsu, Judy E Stern, David B Seifer.   

Abstract

OBJECTIVE: To analyze changes in intracytoplasmic sperm injection (ICSI) utilization, indications, and outcomes across U.S. regions.
METHODS: We conducted a retrospective cohort study. Data sets for 2000-2014 were obtained from the Centers for Disease Control and Prevention. Clinics with 100 or greater fresh, nondonor cycles were grouped by 10 nationally recognized Department of Health and Human Services (DHHS) regions and were compared for use of ICSI, frequency of male factor infertility, preimplantation genetic therapies, pregnancy, and live birth rates per cycle among fresh in vitro fertilization cycles in women younger than 35 years of age.
RESULTS: Nationwide ICSI utilization increased 52% (46.3±6.1% to 70.0±7.1%) from 2000 to 2014, whereas pregnancy and live birth rates per cycle modestly increased by 8.5% (39.2±3.8% to 42.5±2.5%) and 7.6% (34.4±3.6% to 37±2.6%), respectively, showing a positive correlation (r=0.78, P<.001; r=0.76, P=.001) with ICSI rates per clinic. All DHHS Services regions demonstrated increases in ICSI utilization over time, although the magnitude of increase varied in different regions. Regions also had similarities in trends for pregnancy and live birth rates per cycle in women younger than 35 years. There was no correlation between male factor and ICSI rates per clinic from 2000 to 2010 (r=0.32, P=.33) or 2011 to 2014 (r=0.85, P=.068). From 2007 to 2014, ICSI and preimplantation genetic testing did not demonstrate a strong correlation (r=0.68, P=.062).
CONCLUSION: From 2000 to 2014, ICSI rates per clinic significantly varied among geographic regions. Increased use of ICSI did not correlate with an increase in male factor diagnoses. These findings suggest that ICSI may be overused, because its use is not accompanied by proportionate increases in medical indications or effectiveness.

Entities:  

Mesh:

Year:  2018        PMID: 29995722     DOI: 10.1097/AOG.0000000000002730

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  7 in total

1.  Machine-learning algorithm incorporating capacitated sperm intracellular pH predicts conventional in vitro fertilization success in normospermic patients.

Authors:  Stephanie Jean Gunderson; Lis Carmen Puga Molina; Nicholas Spies; Paula Ania Balestrini; Mariano Gabriel Buffone; Emily Susan Jungheim; Joan Riley; Celia Maria Santi
Journal:  Fertil Steril       Date:  2021-01-15       Impact factor: 7.490

Review 2.  Perinatal Outcomes Following Assisted Reproductive Technology.

Authors:  Sesh Kamal Sunkara; Parimala Chinta; Mohan S Kamath
Journal:  J Hum Reprod Sci       Date:  2019 Jul-Sep

3.  Differences in ICSI utilization rates among states with insurance mandates for ART coverage.

Authors:  Pavel Zagadailov; Kyung S Cho; David B Seifer
Journal:  Reprod Biol Endocrinol       Date:  2021-11-30       Impact factor: 5.211

4.  Effectivity of conventional in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) when male factor is absent: a perspective point of view.

Authors:  Marcelo Giacobbe; Maiara Conatti; Alecsandra Gomes; Tatiana Cs Bonetti; Pedro Aa Monteleone
Journal:  JBRA Assist Reprod       Date:  2022-01-17

5.  ICSI in non-male factor infertility patients does not alter metabolomic signature in sibling embryos as evidenced by sensitivity enhanced nuclear magnetic resonance (NMR) spectroscopy.

Authors:  Ameya Jijo; Aswathi Cheredath; Shubhashree Uppangala; Vani Lakshmi R; David Joseph; Huidrom Yaiphaba Meitei; Gitanjali Asampille; Pratap Kumar; Nagana Gowda G A; Guruprasad Kalthur; Borut Kovacic; Satish Kumar Adiga
Journal:  PLoS One       Date:  2022-09-23       Impact factor: 3.752

6.  In vitro fertilisation (IVF) versus intracytoplasmic sperm injection (ICSI) in patients without severe male factor infertility: study protocol for the randomised, controlled, multicentre trial INVICSI.

Authors:  Sine Berntsen; Bugge Nøhr; Marie Louise Grøndahl; Morten Rønn Petersen; Lars Franch Andersen; Anne Lis Englund; Ulla Breth Knudsen; Lisbeth Prætorius; Anne Zedeler; Henriette Svarre Nielsen; Anja Pinborg; Nina La Cour Freiesleben
Journal:  BMJ Open       Date:  2021-06-24       Impact factor: 2.692

7.  Do state insurance mandates alter ICSI utilization?

Authors:  Pavel Zagadailov; David B Seifer; He Shan; Shvetha M Zarek; Albert L Hsu
Journal:  Reprod Biol Endocrinol       Date:  2020-04-25       Impact factor: 5.211

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.